Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation

Autor: Edward L.C. Pritchett, Tonny Nielsen, Benoit Coutu, Craig M. Pratt, John Ip, Ian G. Stiell, Egon Toft, S. Lind Rasmussen, Denis Roy, Christian Torp-Pedersen, Steen Juul-Möller, A. John Camm, D. George Wyse

Publikováno v: Roy, D, Pratt, C M, Torp-Pedersen, C, Wyse, D G, Toft, E, Juul-Moller, S, Nielsen, T, Rasmussen, S L, Stiell, I G, Coutu, B, Ip, J H, Pritchett, E L C & Camm, A J 2008, ' Vernakalant hydrochloride for rapid conversion of atrial fibrillation : a phase 3, randomized, placebo-controlled trial ', Circulation, vol. 117, no. 12, pp. 1518-1525 . https://doi.org/10.1161/CIRCULATIONAHA.107.723866
Roy, D, Pratt, C M, Torp-Pedersen, C, Wyse, D G, Toft, E, Juul-Moller, S, Nielsen, T, Rasmussen, S L, Stiell, I G, Coutu, B, Ip, J H, Pritchett, E L C, Camm, A J & Atrial Arrhythmia Conversion Trial Investigators 2008, ' Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial ', Circulation, vol. 117, no. 12, pp. 1518-25 . https://doi.org/10.1161/CIRCULATIONAHA.107.723866

Background— The present study assessed the efficacy and safety of vernakalant hydrochloride (RSD1235), a novel compound, for the conversion of atrial fibrillation (AF). Methods and Results— Patients were randomized in a 2:1 ratio to receive verna

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97df0b9075bb87afdfd9d7b4493c4256
https://doi.org/10.1161/circulationaha.107.723866

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.